Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

Blockade of the PD-1/PD-L1 immunologic checkpoint using monoclonal antibodies has provided breakthrough therapies against cancer in the recent years. Nevertheless, intrinsic disadvantages of therapeutic antibodies may limit their applications. Thus, blocking of the PD-1/PD-L1 interaction by small mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fengling, Ye, Wenling, Wang, Shuang, He, Yongxing, Zhong, Haiyang, Wang, Yuwei, Zhu, Yongchang, Han, Jianting, Bing, Zhitong, Ji, Shaoping, Liu, Huanxiang, Yao, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851350/
https://www.ncbi.nlm.nih.gov/pubmed/33529880
http://dx.doi.org/10.1016/j.neo.2021.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851350/
https://www.ncbi.nlm.nih.gov/pubmed/33529880
http://dx.doi.org/10.1016/j.neo.2021.01.001

Ejemplares similares